G Quintero Aldana1, M Salgado2, S Candamio3, J C Méndez4, M Jorge5, M Reboredo6, L Vázquez Tuñas7, C Romero8, M Covela9, A Fernández Montes2, M Carmona9, Y Vidal Insua3, R López3,10. 1. Department of Medical Oncology, Hospital Universitario Lucus Augusti, Calle Doctor Ulises Romero, 1, 27003, Lugo, Spain. gquinteroaldana@gmail.com. 2. Department of Medical Oncology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain. 3. Department of Medical Oncology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain. 4. Department of Medical Oncology, Centro Oncologico de Galicia, A Coruña, Spain. 5. Department of Medical Oncology, Complejo Hospitalario Xeral Cíes, Vigo, Spain. 6. Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain. 7. Department of Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain. 8. Department of Medical Oncology, Hospital POVISA, Vigo, Spain. 9. Department of Medical Oncology, Hospital Universitario Lucus Augusti, Calle Doctor Ulises Romero, 1, 27003, Lugo, Spain. 10. CIBERONC, Madrid, Spain.
Abstract
PURPOSE: Panitumumab is extensively used for RAS-WT metastatic colorectal cancer. This study assessed the efficacy and safety of panitumumab plus first-line chemotherapy [docetaxel (DOC) and cisplatin (CIS)] in treatment-naïve advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma (ADC) patients. METHODS: Phase II, open-label, single-arm study includes treatment-naïve advanced gastric or GEJ-ADC patients from ten Spanish centres. Patients received panitumumab (6 mg/kg) plus DOC and CIS (50 mg/m2 both) every 2 weeks until disease progression, unacceptable toxicity, or patient withdrawal. Primary endpoint: objective response rate (ORR); main secondary endpoints: disease control rate (DCR), duration of response (DoR), time to progressive disease (TTP), progression-free-survival (PFS), overall survival (OS), and safety. RESULTS: Forty-four patients were included; median age: 67.8 (range 43.3-82.7) years, 68.2% male. The ORR was 27.3% (95% CI 15.0, 42.8); median PFS and OS: 5.0 (95% CI 3.6, 6.9) and 7.2 (5.5, 9.0) months, respectively. Median TTP, DCR and DoR: 5.3 (range 3.8-7.0) months, 70.5% (95% CI 54.8, 83.2%), and 4.8 (1.8, NE) months. Median panitumumab treatment duration: 11.9 (range 0.1-34.9) weeks; 25.0% patients had a dose reduction and 40.9% discontinued treatment. Grade 3-4 adverse events (AEs): 68.2%/22.2% patients. Most common AEs: asthenia (75.0%) and mucosal inflammation (54.5%). Serious AEs were experienced by 54.6% patients; 9.1%, 13.6%, and 15.9% related to panitumumab, DOC, and CIS, respectively. Three (6.8%) patients died due to AEs not related to study treatment. CONCLUSIONS: The addition of panitumumab to standard chemotherapy as the first-line treatment in advanced gastric or GEJ-ADC does not appear to improve the efficacy outcomes.
PURPOSE:Panitumumab is extensively used for RAS-WT metastatic colorectal cancer. This study assessed the efficacy and safety of panitumumab plus first-line chemotherapy [docetaxel (DOC) and cisplatin (CIS)] in treatment-naïve advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma (ADC) patients. METHODS: Phase II, open-label, single-arm study includes treatment-naïve advanced gastric or GEJ-ADC patients from ten Spanish centres. Patients received panitumumab (6 mg/kg) plus DOC and CIS (50 mg/m2 both) every 2 weeks until disease progression, unacceptable toxicity, or patient withdrawal. Primary endpoint: objective response rate (ORR); main secondary endpoints: disease control rate (DCR), duration of response (DoR), time to progressive disease (TTP), progression-free-survival (PFS), overall survival (OS), and safety. RESULTS: Forty-four patients were included; median age: 67.8 (range 43.3-82.7) years, 68.2% male. The ORR was 27.3% (95% CI 15.0, 42.8); median PFS and OS: 5.0 (95% CI 3.6, 6.9) and 7.2 (5.5, 9.0) months, respectively. Median TTP, DCR and DoR: 5.3 (range 3.8-7.0) months, 70.5% (95% CI 54.8, 83.2%), and 4.8 (1.8, NE) months. Median panitumumab treatment duration: 11.9 (range 0.1-34.9) weeks; 25.0% patients had a dose reduction and 40.9% discontinued treatment. Grade 3-4 adverse events (AEs): 68.2%/22.2% patients. Most common AEs: asthenia (75.0%) and mucosal inflammation (54.5%). Serious AEs were experienced by 54.6% patients; 9.1%, 13.6%, and 15.9% related to panitumumab, DOC, and CIS, respectively. Three (6.8%) patientsdied due to AEs not related to study treatment. CONCLUSIONS: The addition of panitumumab to standard chemotherapy as the first-line treatment in advanced gastric or GEJ-ADC does not appear to improve the efficacy outcomes.
Authors: Jaffer A Ajani; Miguel B Fodor; Sergei A Tjulandin; Vladimir M Moiseyenko; Yee Chao; Sebastiao Cabral Filho; Alejandro Majlis; Sylvie Assadourian; Eric Van Cutsem Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: J A Chan; L S Blaszkowsky; P C Enzinger; D P Ryan; T A Abrams; A X Zhu; J S Temel; D Schrag; P Bhargava; J A Meyerhardt; B M Wolpin; P Fidias; H Zheng; S Florio; E Regan; C S Fuchs Journal: Ann Oncol Date: 2011-01-07 Impact factor: 32.976
Authors: G Quintero-Aldana; M Jorge; C Grande; M Salgado; E Gallardo; S Varela; C López; M J Villanueva; A Fernández; E Alvarez; P González; J Castellanos; J Casal; R López; B Campos Balea Journal: Cancer Chemother Pharmacol Date: 2015-08-05 Impact factor: 3.333
Authors: Niall C Tebbutt; Timothy J Price; Danielle A Ferraro; Nicole Wong; Anne-Sophie Veillard; Merryn Hall; Katrin M Sjoquist; Nick Pavlakis; Andrew Strickland; Suresh C Varma; Prasad Cooray; Rosemary Young; Craig Underhill; Jennifer A Shannon; Vinod Ganju; Val Gebski Journal: Br J Cancer Date: 2016-02-11 Impact factor: 7.640